A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype

被引:28
|
作者
Chida, M
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam,Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
[4] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*18; genotype;
D O I
10.1097/00008571-199906000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Two poor metabolizer individuals of debrisoquine were identified among 215 healthy Japanese by a phenotyping test, Analysis of the CYP2D6 gene from one of two poor metabolizers, who was not homozygous for the previously described CYP2D6 Variant alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*18), showed that this individual was heterozygous for a new allele, CYP2D6/C8 (CYP2D6*21), CYP2D6*21 I had a single cytosine insertion at position 2661 in exon 5, This cytosine insertion generated a stop codon at the 17 bp downstream of this insertion site, A method to detect this allele was established with an allele specific-polymerase chain reaction, This method showed that another one of two poor metabolizers also possessed CYP2D6*21 allele heterozygously, In 318 healthy Japanese, five individuals carried this allele, heterozygously (0.81%, 5/636 chromosomes), Based on the present and our previous data, the poor metabolizer frequency in Japanese was estimated to be 0.39%, which accounted for approximately 45% of the individuals phenotyped as poor metabolizers by in-vivo tests. Pharmacogenetics 9:287-293 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 50 条
  • [41] Genotype and allele frequency of CYP2D6 in Tamilian population
    Adithan, C
    Gerard, N
    Naveen, AT
    Koumaravelou, K
    Shashindran, CH
    Krishnamoorthy, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (07) : 517 - 520
  • [42] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [43] Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome
    Dilger, K
    Meisel, P
    Hofmann, U
    Eichelbaum, M
    THERAPEUTIC DRUG MONITORING, 2000, 22 (03) : 366 - 368
  • [44] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    de la Torre, R
    Farré, M
    Mathúna, BO
    Roset, PN
    Pizarro, N
    Segura, M
    Torrens, M
    Ortuño, J
    Pujadas, M
    Camí, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 551 - 554
  • [45] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    Rafael de la Torre
    Magí Farré
    Brian Ó Mathúna
    Pere N. Roset
    Neus Pizarro
    Mireia Segura
    Marta Torrens
    Jordi Ortuño
    Mitona Pujadas
    Jordi Camí
    European Journal of Clinical Pharmacology, 2005, 61 : 551 - 554
  • [46] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
  • [47] A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples
    Collins, Joseph M. M.
    Lester, Hannah
    Shabnaz, Samia
    Wang, Danxin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [48] New allelic arrangement CYP2D6*36x2 found in a Japanese poor metabolizer of debrisoquine
    Chida, M
    Ariyoshi, N
    Yokoi, T
    Nemoto, N
    Inaba, M
    Kinoshita, M
    Kamataki, T
    PHARMACOGENETICS, 2002, 12 (08): : 659 - 662
  • [49] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6
    MCLEOD, HL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 463 - 463
  • [50] CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
    Almoguera, Berta
    Riveiro-Alvarez, Rosa
    Lopez-Castroman, Jorge
    Dorado, Pedro
    Vaquero-Lorenzo, Concepcion
    Fernandez-Piqueras, Jose
    LLerena, Adrian
    Abad-Santos, Francisco
    Baca-Garcia, Enrique
    Dal-Re, Rafael
    Ayuso, Carmen
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (11): : 627 - 630